GRAIL (GRAL) Expected to Announce Earnings on Wednesday

GRAIL (NASDAQ:GRAL) is projected to post its Q3 2025 results after the market closes on Wednesday, November 12th. Analysts expect GRAIL to post earnings of ($3.40) per share and revenue of $33.8330 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:30 PM ET.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($3.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.14) by ($0.04). The business had revenue of $35.54 million for the quarter, compared to analyst estimates of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. On average, analysts expect GRAIL to post $-15 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

GRAIL Price Performance

Shares of GRAIL stock opened at $80.69 on Wednesday. GRAIL has a 52-week low of $13.52 and a 52-week high of $103.00. The firm has a market capitalization of $2.91 billion, a PE ratio of -6.15 and a beta of 4.31. The company’s fifty day moving average price is $59.03 and its two-hundred day moving average price is $45.66.

Insider Activity

In other news, CEO Robert P. Ragusa sold 7,239 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $68.88, for a total transaction of $498,622.32. Following the completion of the sale, the chief executive officer owned 727,388 shares of the company’s stock, valued at approximately $50,102,485.44. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Joshua J. Ofman sold 6,114 shares of GRAIL stock in a transaction that occurred on Thursday, October 16th. The shares were sold at an average price of $82.01, for a total transaction of $501,409.14. Following the completion of the transaction, the president owned 381,818 shares of the company’s stock, valued at $31,312,894.18. This trade represents a 1.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 117,497 shares of company stock worth $7,515,436 over the last ninety days.

Hedge Funds Weigh In On GRAIL

A number of institutional investors and hedge funds have recently bought and sold shares of GRAL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of GRAIL by 28.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,835 shares of the company’s stock worth $76,000 after purchasing an additional 623 shares during the last quarter. NewEdge Advisors LLC lifted its position in GRAIL by 44.0% during the 2nd quarter. NewEdge Advisors LLC now owns 2,535 shares of the company’s stock worth $130,000 after buying an additional 775 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in GRAIL by 120.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,513 shares of the company’s stock worth $129,000 after acquiring an additional 1,375 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in GRAIL by 278.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,288 shares of the company’s stock valued at $118,000 after acquiring an additional 1,684 shares in the last quarter. Finally, Osaic Holdings Inc. increased its position in GRAIL by 33.7% in the 2nd quarter. Osaic Holdings Inc. now owns 8,880 shares of the company’s stock valued at $456,000 after acquiring an additional 2,240 shares in the last quarter.

Analysts Set New Price Targets

GRAL has been the topic of a number of analyst reports. UBS Group set a $75.00 target price on shares of GRAIL in a research note on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group raised their target price on GRAIL from $75.00 to $85.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.00.

About GRAIL

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.